Victory Capital Management
BTTX

Victory Capital Management’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Victory Capital Management’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-272,720
Closed -$540K – 2764
2022
Q1 		$540K Buy
+272,720
New +$943K ﹤0.01% 2100

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Victory Capital Management's BTTX Position: Q2 2022 in Review

Victory Capital Management sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q2 2022, closing a stake of 272,720 shares — an estimated $540K sold.

Victory Capital Management first reported a position in BTTX in Q1 2022 and held it in 1 quarter. The position peaked at $540K in Q1 2022. 14 funds tracked by Wall St. Rank hold BTTX as of Q2 2022.

  • Victory Capital Management reported no remaining Better Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Victory Capital Management sold 272,720 Better Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $540K.
  • Victory Capital Management first reported a position in Better Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Victory Capital Management's Better Therapeutics, Inc. Common Stock position peaked at $540K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Victory Capital Management's 13F filing for Q2 2022, filed 1 Aug 2022.